For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
8
views
24
references
 Top references
cited by
6
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      442
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction

      abstract

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Atrial fibrillation (AFib) is frequently associated with heart failure. Guidelines for AFib management have been recently updated and include an algorithm for acute heart rate control based on left ventricular ejection fraction and haemodynamics. Landiolol is an injectable ultra-short beta-blocker with very high beta-1 selectivity, listed in Japanese Guidelines for AFib management as potential option for rate control of patient with heart failure. Landiolol is now available in Europe with indication of controlling heart rate in AFib and supraventricular tachycardia. This review discusses existing clinical data in Japan and perspectives of landiolol use for acute rate control of AFib patients with cardiac dysfunction.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: not found

          Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry

          Naoki Sato, Aldo P. Maggioni, Yuhui Zhang … (2017)
          Several clinical conditions may precipitate acute heart failure (AHF) and influence clinical outcome. In this study we hypothesized that precipitating factors are independently associated with 90-day risk of death in AHF.
          Article 0 comments Cited 51 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry.

            Michael Fu, Max Petzold, Shi-Jun Li … (2015)
            In heart failure and reduced ejection fraction, the prognostic role of heart rate (HR) in atrial fibrillation (AF) is unknown and the effectiveness of β-blockers has recently been questioned in AF.
            Article 0 comments Cited 44 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study).

              Katsuhiro Fujino, Tetsuji Nagano, Hiroshi Inoue … (2012)
              A rapid heart rate (HR) during atrial fibrillation (AF) and atrial flutter (AFL) in left ventricular (LV) dysfunction often impairs cardiac performance. The J-Land study was conducted to compare the efficacy and safety of landiolol, an ultra-short-acting β-blocker, with those of digoxin for swift control of tachycardia in AF/AFL in patients with LV dysfunction. The 200 patients with AF/AFL, HR ≥120beats/min, and LV ejection fraction 25-50% were randomized to receive either landiolol (n=93) or digoxin (n=107). Successful HR control was defined as ≥20% reduction in HR together with HR <110beats/min at 2h after starting intravenous administration of landiolol or digoxin. The dose of landiolol was adjusted in the range of 1-10µg·kg(-1)·min(-1) according to the patient's condition. The mean HR at baseline was 138.2±15.7 and 138.0±15.0beats/min in the landiolol and digoxin groups, respectively. Successful HR control was achieved in 48.0% of patients treated with landiolol and in 13.9% of patients treated with digoxin (P<0.0001). Serious adverse events were reported in 2 and 3 patients in each group, respectively. Landiolol was more effective for controlling rapid HR than digoxin in AF/AFL patients with LV dysfunction, and could be considered as a therapeutic option in this clinical setting.
              Article 0 comments Cited 38 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Eur Heart J Suppl
                Journal ID (iso-abbrev): Eur Heart J Suppl
                Journal ID (publisher-id): ehjsupp
                Title: European Heart Journal Supplements : Journal of the European Society of Cardiology
                Publisher: Oxford University Press
                ISSN (Print): 1520-765X
                ISSN (Electronic): 1554-2815
                Publication date (Print): January 2018
                Publication date (Electronic): 08 January 2018
                Publication date PMC-release: 08 January 2018
                Volume: 20
                Issue: Suppl A , Landiolol: A new agent for Acute Rate Control in Atrial Fibrillation
                Pages: A19-A24
                Affiliations
                [1 ]Department of Cardiology and Pneumology, University of Göttingen Medical Center, Robert-Koch-Strasse 40, DE-37075 Göttingen, Germany
                [2 ]Department of Internal Medicine, Cardiovascular Medicine, General Teaching Hospital and 1st Faculty of Medicine, Charles University, U Nemocnice 2, Praha 2, 128 00 Prague, Czech Republic
                [3 ]Department of Cardiology, Rhythmology and Intensive Care Medicine, Klinikum Gütersloh, Germany
                [4 ]Department of Anaesthesia and Critical Care Medicine, Cardiothoracic and Vascular Anaesthesia, Azienda Ospedaliero Universitaria Pisana, Via Roma n. 67, 56126 Pisa, Italy
                [5 ]Department of Clinical Research and Pharmaceutical Development, Amomed Pharma GmbH Vienna, Austria
                Author notes
                Corresponding author. Tel: +49 551 39 20911, Fax: +49 551 39 20918, Email: stephan.von.haehling@ 123456med.uni-goettingen.de
                Article
                Publisher ID: sux035
                DOI: 10.1093/eurheartj/sux035
                PMC ID: 5909772
                PubMed ID: 30188957
                SO-VID: 0fcabd4e-1349-40f3-adbc-107f0ff59187
                Copyright © Published on behalf of the European Society of Cardiology. © The Author 2018.
                License:

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                Page count
                Pages: 6
                Categories
                Subject: Articles

                Keywords: atrial fibrillation,beta-blockers,landiolol,heart failure,supraventricular tachycardia
                Data availability:
                Keywords: atrial fibrillation, beta-blockers, landiolol, heart failure, supraventricular tachycardia

                Comments

                Comment on this article

                scite_

                Similar content442

                See all similar

                Cited by6

                See all cited by

                Most referenced authors817

                See all reference authors